ReviewCell communication and signaling : CCS2025
Long interspersed nuclear element 1 methylation in non-small cell lung cancer: implications for diagnosis, prognosis, and therapeutic targeting.
Review in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The nutrigenomic-epigenetic axis in cancer: from dietary bioactives to precision oncology.Nutrition & metabolism · 2026Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long interspersed nucleotide element 1 (LINE1), the most abundant repetitive element in the human genome, plays a crucial role in genomic instability. Aberrant LINE1 activation, primarily regulated by DNA methylation, is a hallmark of cancer. Non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer worldwide, continues to pose significant challenges due to the invasiveness, high cost, and susceptibility to false positives of current diagnostic methods, as well as the emergence of treatment resistance. This review highlights the potential of LINE1 methylation as a biomarker for NSCLC, offering novel insights into its role in diagnosis, prognosis, and therapeutic strategies. Recent studies uncovered that LINE1 hypomethylation was strongly associated with poor overall survival, suggesting its utility as both a prognostic marker and a therapeutic target. However, further research is required to elucidate its precise regulatory mechanisms in LINE1 retrotransposition and to evaluate its potential as a non-invasive biomarker for improving NSCLC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.